Consequently, according to ESC guidelines on the management of CVD in individuals with diabetes, SGLT2 inhibitors and GLP1-RAs are the recommended treatments in those with a high risk of ASCVD, independent of glucose control considerations and independent of background metformin use [72]. Here, SLC5A2 is linked to diabetes mellitus.